The controversy behind the new FDA-approved drug for Alzheimer’s disease

image-institute-douglas_cc-by-nc-nd

Rana Semaan, Science in Society editor On June 7, 2021, the U.S. Food and Drug Administration (FDA) approved the drug Aduhelm™ (aducanumab-avwa) for the treatment of Alzheimer’s disease under its accelerated approval pathway. I felt overjoyed and excited reading this news. I’d seen the disease up close and lost my grandmother to Alzheimer’s. I immediately […]

Continue reading